Whitehawk Therapeutics, Inc. Common Stock WHWK Business Segments
| FY'25 | ||
|---|---|---|
| Research And Development Expense Excluding Acquired In Process Cost by Product | ||
| Antibody Drug Conjugate | $59.09M+885% | |
| FYARRO | $5.17M-84.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Whitehawk Therapeutics, Inc. Common Stock break its business down?
- Whitehawk Therapeutics, Inc. Common Stock (WHWK) reports research and development expense excluding acquired in process cost by product across 2 parts — Antibody Drug Conjugate and FYARRO. Each is extracted from the segment footnotes and tracked over time.
- Where does Whitehawk Therapeutics, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Whitehawk Therapeutics, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.